At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 10, 2026 at 16:01 ET
Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold urticaria, plus a late-breaking poster on first-in-human Phase 1 results for CDX-622, a bispecific targeting TSLP and mast cells. This is a routine scientific conference update with no new efficacy or safety data disclosed, providing no material stock-moving catalyst.
- Three presentations to be given at EAACI Annual Congress, June 12-15, 2026, in Istanbul, Türkiye
- Two flash talks on barzolvolimab: one on long-term off-treatment angioedema improvement in CSU, another on psychometric validation of WI-NRS in cold urticaria
- Late-breaking poster on Phase 1 first-in-human results of CDX-622 (bispecific targeting TSLP and mast cells via SCF) in healthy volunteers
- Barzolvolimab is in Phase 3 studies for CSU and ColdU/SD, and Phase 2 studies for prurigo nodularis and atopic dermatitis
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access